Zhengyang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhengyang Liu has a total of 127 co-authors. Here are the top co-authors by number of shared publications:
- Dhruvesh M. Ramson
Department of Surgery Monash University Melbourne Victoria Australia
9 shared publications - Luke A. Perry
Victorian Cardiac Anaesthesia Research Laboratory, Department of Surgery, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia
9 shared publications - Jahan C. Penny-Dimri
Department of Surgery; Monash University; Melbourne Australia
6 shared publications Luke A. Perry
Department of Surgery Monash University Melbourne Victoria Australia
6 shared publications- Dev Raveendran
Department of Surgery, The Royal Melbourne Hospital, Parkville, VIC, Australia
5 shared publications - Julian A. Smith
Department of Surgery Monash University Melbourne Victoria Australia
5 shared publications
Latest Publications
- 5 October 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
The effectiveness of punch grafting for stable vitiligo
- 5 October 2026
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
The effectiveness of punch grafting for stable vitiligo
- 8 September 2026
- Published by SAGE Publications in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- Vol. 19
The Association Between Platelet Indices and Osteoarthritis: A Systematic Review and Meta-analysis
Background: The role of routinely available platelet biomarkers – platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW) and plateletcrit (PCT) – is poorly understood in osteoarthritis (OA). This systematic review and meta-analysis aimed to assess the association between platelet biomarkers and the occurrence and severity of OA. Methods: MEDLINE, Embase and the Cochrane libraries were searched from inception to June 2025. We included studies reporting on the association between PLT, MPV, PDW and PCT with the presence and severity of OA. We tabulated mean differences (MDs) of platelet biomarkers between patients with OA against healthy controls, as well as between patients with severe OA and mild/moderate OA to generate pooled effect measures using random-effects inverse variance modelling. Results: Fourteen studies, with a total of 13 843 patients, were included in this systematic review. Mean platelet volume (fL) was significantly reduced in OA as compared to healthy controls, MD = −0.52 (95% CI: −0.65 to −0.39, P < .01). Platelet count was not significantly different between the groups, MD = 2.32 (95% CI: −6.29 to 10.94, P = .60). Both PLT and MPV were not significantly different between the 2 groups, with pooled mean differences of 3.57 (95% CI = −8.21 to 15.35, P = .55) and 0.37 (95% CI = −0.33 to 1.08, P = .30), respectively. Conclusions: This meta-analysis found MPV to be significantly reduced in OA. Further studies are needed to further evaluate the prognostic significance of mean platelet volume in OA.
- 8 September 2026
- Published by SAGE Publications in Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders
- Vol. 19
The Association Between Platelet Indices and Osteoarthritis: A Systematic Review and Meta-analysis
Background: The role of routinely available platelet biomarkers – platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW) and plateletcrit (PCT) – is poorly understood in osteoarthritis (OA). This systematic review and meta-analysis aimed to assess the association between platelet biomarkers and the occurrence and severity of OA. Methods: MEDLINE, Embase and the Cochrane libraries were searched from inception to June 2025. We included studies reporting on the association between PLT, MPV, PDW and PCT with the presence and severity of OA. We tabulated mean differences (MDs) of platelet biomarkers between patients with OA against healthy controls, as well as between patients with severe OA and mild/moderate OA to generate pooled effect measures using random-effects inverse variance modelling. Results: Fourteen studies, with a total of 13 843 patients, were included in this systematic review. Mean platelet volume (fL) was significantly reduced in OA as compared to healthy controls, MD = −0.52 (95% CI: −0.65 to −0.39, P < .01). Platelet count was not significantly different between the groups, MD = 2.32 (95% CI: −6.29 to 10.94, P = .60). Both PLT and MPV were not significantly different between the 2 groups, with pooled mean differences of 3.57 (95% CI = −8.21 to 15.35, P = .55) and 0.37 (95% CI = −0.33 to 1.08, P = .30), respectively. Conclusions: This meta-analysis found MPV to be significantly reduced in OA. Further studies are needed to further evaluate the prognostic significance of mean platelet volume in OA.
- Open Access
Effect of iStent inject on unmedicated intraocular pressure in glaucoma: exploratory analysis of clinical trial data
Purpose The direct effect of iStent inject on intraocular pressure (IOP) in patients with glaucoma is difficult to quantify in pragmatic trials where rates of post-surgical IOP-lowering therapy differ between intervention groups. We aimed to quantify the causal effect of iStent inject on unmedicated IOP at 12- and 24-months post-surgery. Methods Adults with mild-to-moderate glaucoma were 1:1 randomised to receive cataract surgery with iStent inject or cataract surgery alone at an Australian hospital (2017-2020, NCT03106181 ). IOP-lowering medications were prescribed as per clinician discretion. An exploratory analysis was used to estimate the controlled direct effect of iStent inject on IOP, analogous to the effect expected if all participants had undergone medication washout prior to assessment. Results Ninety-five eyes from 80 people were included (67.4% male, mean age 73.0 years, mean baseline IOP 17.1 mmHg). IOP-lowering medication was required for 53% of eyes in each group at 12 months (n=76); at 24 months (n=86) it was required for 43% and 64% in the active and control groups, respectively. Mean IOP was similar between intervention groups at each outcome visit. The controlled direct effect favoured the iStent inject group at 12 months (-2.1-mmHg difference, 95% CI -4.0,-0.3) but was attenuated at 24 months (-0.5 mmHg-difference, 95% CI -2.6,1.6). Conclusion Although the iStent inject was estimated to have an effect on lowering unmedicated IOP at 12 months, this effect had largely disappeared by 24 months. Medication washout is recommended when safe and practical in future trials to estimate these direct effects with more certainty.
Open AccessEffect of iStent inject on unmedicated intraocular pressure in glaucoma: exploratory analysis of clinical trial data
Purpose The direct effect of iStent inject on intraocular pressure (IOP) in patients with glaucoma is difficult to quantify in pragmatic trials where rates of post-surgical IOP-lowering therapy differ between intervention groups. We aimed to quantify the causal effect of iStent inject on unmedicated IOP at 12- and 24-months post-surgery. Methods Adults with mild-to-moderate glaucoma were 1:1 randomised to receive cataract surgery with iStent inject or cataract surgery alone at an Australian hospital (2017-2020, NCT03106181 ). IOP-lowering medications were prescribed as per clinician discretion. An exploratory analysis was used to estimate the controlled direct effect of iStent inject on IOP, analogous to the effect expected if all participants had undergone medication washout prior to assessment. Results Ninety-five eyes from 80 people were included (67.4% male, mean age 73.0 years, mean baseline IOP 17.1 mmHg). IOP-lowering medication was required for 53% of eyes in each group at 12 months (n=76); at 24 months (n=86) it was required for 43% and 64% in the active and control groups, respectively. Mean IOP was similar between intervention groups at each outcome visit. The controlled direct effect favoured the iStent inject group at 12 months (-2.1-mmHg difference, 95% CI -4.0,-0.3) but was attenuated at 24 months (-0.5 mmHg-difference, 95% CI -2.6,1.6). Conclusion Although the iStent inject was estimated to have an effect on lowering unmedicated IOP at 12 months, this effect had largely disappeared by 24 months. Medication washout is recommended when safe and practical in future trials to estimate these direct effects with more certainty.
- 21 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis
Aim: To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema. Methods: We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24–40 weeks), with 4 weekly aflibercept 2 mg as the common comparator. Results: Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30–60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47). Conclusion: Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation. PROSPERO registration number: CRD420251249785.
- 21 August 2026
- Published by BMJ in British Journal of Ophthalmology
Aflibercept 8 mg versus faricimab for macular oedema due to retinal vein occlusion: a systematic review and network meta-analysis
Aim: To indirectly evaluate the comparative efficacy and safety of aflibercept 8 mg and faricimab in treating retinal vein occlusion (RVO)-associated macular oedema. Methods: We searched MEDLINE, Embase and Cochrane CENTRAL from inception to 11 December 2025. We performed frequentist network meta-analysis on efficacy and safety outcomes at loading phase completion (24–40 weeks), with 4 weekly aflibercept 2 mg as the common comparator. Results: Three trials with 2174 adults were included. 8 weekly aflibercept 8 mg with five 4 weekly loading doses was more likely to achieve a best corrected visual acuity (BCVA) of ≥69 letters (Snellen 20/40, unconditional driving threshold) compared with 4 weekly faricimab (risk ratio (RR) 1.18, 95% CI 1.03 to 1.35). 4 weekly faricimab demonstrated greater rates of complete resolution of intraretinal and subretinal fluid against 8 weekly aflibercept 8 mg with both five and three 4 weekly loading doses (both RR 1.12, 95% CI 1.01 to 1.25). There was no evidence of a difference in mean BCVA improvement between agents. Both aflibercept 8 mg and 2 mg regimens were associated with a greater risk of clinically significant intraocular pressure (IOP) rise of 30–60 min post-injection compared with 4 weekly faricimab (8 weekly aflibercept 8 mg with five 4 weekly loading doses, RR 6.42, 95% CI 1.85 to 22.34; 8 weekly aflibercept 8 mg with three 4 weekly loading doses, RR 6.97, 95% CI 2.02 to 24.08; 4 weekly aflibercept 2 mg, RR 2.12, 95% CI 1.01 to 4.47). Conclusion: Aflibercept 8 mg and faricimab show comparable overall visual efficacy for RVO-associated macular oedema. Indirect comparisons suggest aflibercept 8 mg may increase the probability of achieving driving vision, while faricimab may offer greater anatomical drying and a lower risk of acute IOP elevation. PROSPERO registration number: CRD420251249785.
- 12 June 2026
- Published by Elsevier in Ophthalmology
Reply
- 28 April 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (4) , CD014901
Early versus late surgical start times for on-pump cardiac surgery
Circadian rhythms affect cardiovascular function, and the timing and severity of stroke and myocardial infarction (commonly known as a heart attack). Afternoon cardiac surgery may improve outcomes by reducing ischaemia-reperfusion injury (i.e. reducing tissue damage caused when blood supply returns to tissue (reperfusion) after a period of oxygen deprivation (ischaemia)). However, the evidence is conflicting. This systematic review assessed the impact of surgical timing on clinical outcomes after cardiac surgery. To assess the effects of early versus late surgical start times for on-pump cardiac surgery on mortality, cardiac outcomes, and quality of life. We searched CENTRAL, MEDLINE, Embase, and Web of Science Conference Proceedings Citation Index - Science, along with ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform trials registers. We also conducted reference checking, citation searching, and contacted study authors to identify studies for inclusion. The latest search date was 26 January 2025. We included randomised controlled trials (RCTs) in adults undergoing cardiac surgery comparing late with early surgical start times. We excluded non-randomised studies and studies in children. Our critical outcomes were short-term mortality (≤ 30 days postoperative), long-term mortality (> 30 days postoperative), and perioperative myocardial infarction. Other important outcomes were perioperative myocardial injury, postoperative atrial fibrillation, left ventricular ejection fraction, lengths of intensive care unit (ICU) and hospital stays, and quality of life. We used the Cochrane Risk of Bias 2 tool to assess bias in the included RCTs. As only one study met the inclusion criteria, we did not perform meta-analysis. We synthesised results descriptively, and used GRADE to assess the certainty of the evidence for specified outcomes. We included one study with 88 participants. The included study was conducted in France, and reported on differences in outcomes between morning and afternoon on-pump elective aortic valve replacement in adults. Critical outcomes No study reported short-term or long-term mortality data for early versus late surgical start times for on-pump cardiac surgery. In the included study, there was no evidence of a difference regarding in-hospital mortality between groups, with no deaths in both groups (risk ratio (RR) and 95% confidence interval (CI) not estimable; 1 study, 88 participants). The evidence is very uncertain about the effect of early versus late surgery on perioperative myocardial infarction (RR 0.29, 95% CI 0.06 to 1.30; 1 study, 88 participants, very low-certainty evidence). Important outcomes There was evidence of lower perioperative myocardial injury as measured by cumulative troponin release over 72 hours in those undergoing late surgery compared to early surgery (MD -46 ng/L × 72 h, 95% CI -79 to -13; 1 study, 88 participants). In the included study, there was no evidence of a difference in new-onset postoperative atrial fibrillation during hospital stay between groups (RR 0.75, 95% CI 0.40 to 1.40; 1 study, 88 participants). No study reported differences in left ventricular ejection fraction at discharge as a continuous variable for early versus late surgical start times for on-pump cardiac surgery. In the included study, there was no evidence of a difference in left ventricular ejection fraction < 45% at discharge between groups (RR 0.40, 95% CI 0.08 to 1.95; 1 study, 88 participants). No study reported differences in length of ICU admission for early versus late surgical start times for on-pump cardiac surgery. There was no evidence of a difference in need for inotropic support between groups in the included study (RR 0.25, 95% CI 0.03 to 2.15; 1 study, 88 participants). The evidence is very uncertain about the effect of late surgery on length of hospital stay (MD 0.00, 95% CI -1.48 to 1.48; 1 study, 88 participants, very low-certainty evidence). No study reported on the outcome of quality of life. The evidence is very uncertain about the effects of early versus late surgical start time for the outcomes of perioperative myocardial infarction and length of hospital stay. We found no data for the outcomes of short-term or long-term mortality, left ventricular ejection fraction, length of ICU stay, or quality of life. Late surgical start time could reduce the risk of perioperative myocardial injury as estimated by cumulative troponin release over 72 hours. More research is needed to determine whether scheduling heart surgery later in the day improves patient outcomes. This Cochrane review had no dedicated funding. Protocol (2022) DOI: 10.1002/14651858.CD014901.
- 28 April 2026
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2026 (4) , CD014901
Early versus late surgical start times for on-pump cardiac surgery
Circadian rhythms affect cardiovascular function, and the timing and severity of stroke and myocardial infarction (commonly known as a heart attack). Afternoon cardiac surgery may improve outcomes by reducing ischaemia-reperfusion injury (i.e. reducing tissue damage caused when blood supply returns to tissue (reperfusion) after a period of oxygen deprivation (ischaemia)). However, the evidence is conflicting. This systematic review assessed the impact of surgical timing on clinical outcomes after cardiac surgery. To assess the effects of early versus late surgical start times for on-pump cardiac surgery on mortality, cardiac outcomes, and quality of life. We searched CENTRAL, MEDLINE, Embase, and Web of Science Conference Proceedings Citation Index - Science, along with ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform trials registers. We also conducted reference checking, citation searching, and contacted study authors to identify studies for inclusion. The latest search date was 26 January 2025. We included randomised controlled trials (RCTs) in adults undergoing cardiac surgery comparing late with early surgical start times. We excluded non-randomised studies and studies in children. Our critical outcomes were short-term mortality (≤ 30 days postoperative), long-term mortality (> 30 days postoperative), and perioperative myocardial infarction. Other important outcomes were perioperative myocardial injury, postoperative atrial fibrillation, left ventricular ejection fraction, lengths of intensive care unit (ICU) and hospital stays, and quality of life. We used the Cochrane Risk of Bias 2 tool to assess bias in the included RCTs. As only one study met the inclusion criteria, we did not perform meta-analysis. We synthesised results descriptively, and used GRADE to assess the certainty of the evidence for specified outcomes. We included one study with 88 participants. The included study was conducted in France, and reported on differences in outcomes between morning and afternoon on-pump elective aortic valve replacement in adults. Critical outcomes No study reported short-term or long-term mortality data for early versus late surgical start times for on-pump cardiac surgery. In the included study, there was no evidence of a difference regarding in-hospital mortality between groups, with no deaths in both groups (risk ratio (RR) and 95% confidence interval (CI) not estimable; 1 study, 88 participants). The evidence is very uncertain about the effect of early versus late surgery on perioperative myocardial infarction (RR 0.29, 95% CI 0.06 to 1.30; 1 study, 88 participants, very low-certainty evidence). Important outcomes There was evidence of lower perioperative myocardial injury as measured by cumulative troponin release over 72 hours in those undergoing late surgery compared to early surgery (MD -46 ng/L × 72 h, 95% CI -79 to -13; 1 study, 88 participants). In the included study, there was no evidence of a difference in new-onset postoperative atrial fibrillation during hospital stay between groups (RR 0.75, 95% CI 0.40 to 1.40; 1 study, 88 participants). No study reported differences in left ventricular ejection fraction at discharge as a continuous variable for early versus late surgical start times for on-pump cardiac surgery. In the included study, there was no evidence of a difference in left ventricular ejection fraction < 45% at discharge between groups (RR 0.40, 95% CI 0.08 to 1.95; 1 study, 88 participants). No study reported differences in length of ICU admission for early versus late surgical start times for on-pump cardiac surgery. There was no evidence of a difference in need for inotropic support between groups in the included study (RR 0.25, 95% CI 0.03 to 2.15; 1 study, 88 participants). The evidence is very uncertain about the effect of late surgery on length of hospital stay (MD 0.00, 95% CI -1.48 to 1.48; 1 study, 88 participants, very low-certainty evidence). No study reported on the outcome of quality of life. The evidence is very uncertain about the effects of early versus late surgical start time for the outcomes of perioperative myocardial infarction and length of hospital stay. We found no data for the outcomes of short-term or long-term mortality, left ventricular ejection fraction, length of ICU stay, or quality of life. Late surgical start time could reduce the risk of perioperative myocardial injury as estimated by cumulative troponin release over 72 hours. More research is needed to determine whether scheduling heart surgery later in the day improves patient outcomes. This Cochrane review had no dedicated funding. Protocol (2022) DOI: 10.1002/14651858.CD014901.
- 21 January 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (1) , e70065
Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis
Excimer 308‐nm light is often used for vitiligo treatment in combination with adjuvants. We aimed to evaluate the efficacy of these combination therapies. We searched MEDLINE, Embase and the Cochrane Library from inception to November 2024. All randomised trials reporting efficacy outcomes for vitiligo patients treated with excimer 308‐nm light were included. Primary outcomes were achieving ≥ 50%, ≥ 75% and 100% skin repigmentation. Pairwise comparisons of treatment repigmentation were summarised as risk ratios (RRs) with 95% confidence intervals (CIs) and a frequentist, random‐effects network meta‐analysis with a graph‐theoretical approach was used to generate summary estimates. Thirty‐eight studies involving 1841 participants were included. Excimer 308‐nm light with topical calcineurin inhibitors or topical corticosteroids significantly improved repigmentation outcomes compared to excimer monotherapy with ≥ 50% (RR 1.47, 95% CI 1.19–1.81; RR 1.65, 95% CI 1.32–2.06) and ≥ 100% repigmentation (RR 1.60, 95% CI 1.03–2.49; RR 2.31, 95% CI 1.50–3.56) respectively. Excimer in combination with topical antioxidants (RR 43.00, 95% CI 2.68–688.68), intramuscular corticosteroid (RR 1.76, 95% CI 1.13–2.74) and platelet rich plasma (RR 1.76, 95% CI 1.32–2.35) enhanced ≥ 50% repigmentation. These findings highlight the value of combination therapy with excimer light as a useful option in the management of vitiligo.
- 21 January 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (1) , e70065
Excimer 308‐Nm Light in the Combination Treatment of Vitiligo: A Systematic Review and Network Meta‐Analysis
Excimer 308‐nm light is often used for vitiligo treatment in combination with adjuvants. We aimed to evaluate the efficacy of these combination therapies. We searched MEDLINE, Embase and the Cochrane Library from inception to November 2024. All randomised trials reporting efficacy outcomes for vitiligo patients treated with excimer 308‐nm light were included. Primary outcomes were achieving ≥ 50%, ≥ 75% and 100% skin repigmentation. Pairwise comparisons of treatment repigmentation were summarised as risk ratios (RRs) with 95% confidence intervals (CIs) and a frequentist, random‐effects network meta‐analysis with a graph‐theoretical approach was used to generate summary estimates. Thirty‐eight studies involving 1841 participants were included. Excimer 308‐nm light with topical calcineurin inhibitors or topical corticosteroids significantly improved repigmentation outcomes compared to excimer monotherapy with ≥ 50% (RR 1.47, 95% CI 1.19–1.81; RR 1.65, 95% CI 1.32–2.06) and ≥ 100% repigmentation (RR 1.60, 95% CI 1.03–2.49; RR 2.31, 95% CI 1.50–3.56) respectively. Excimer in combination with topical antioxidants (RR 43.00, 95% CI 2.68–688.68), intramuscular corticosteroid (RR 1.76, 95% CI 1.13–2.74) and platelet rich plasma (RR 1.76, 95% CI 1.32–2.35) enhanced ≥ 50% repigmentation. These findings highlight the value of combination therapy with excimer light as a useful option in the management of vitiligo.
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Association of Platelet Count, Mean Platelet Volume, Platelet Distribution Width, Plateletcrit, and Platelet–Lymphocyte Ratio With Postoperative Cardiac Surgery–Associated Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Background: The predictive value of platelet indices, including the platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), and platelet–lymphocyte ratio (PLR) for postoperative atrial fibrillation (POAF) following cardiac surgery remains undetermined. Methods: MEDLINE, Embase, and the Cochrane Library were searched from inception to October 2024. For each included study, median differences (MDs) and odds ratios (ORs) were tabulated with 95% confidence intervals (CIs). Pooled estimates were generated using random‐effects inverse‐variance modeling. Statistical analysis focused on cases of POAF. Results: Six thousand five hundred and seventeen unique studies were screened and included 23 studies involving 12,375 patients in the subsequent analysis. Compared with patients who did not develop POAF, patients with POAF had higher preoperative MPV (MD: 0.30 fL, 95% CI: 0.07–0.53, and p = 0.0112) and PLR (MD: 40.42, 95% CI: 7.49–73.33, and p = 0.0161). Preoperative PLT (MD: 3.32, 95% CI: −5.87–12.51, and p = 0.4785) was not significantly different between groups. Study numbers were insufficient to assess the association between PCT with POAF. Conclusion: Elevated preoperative MPV and PLR were associated with POAF after cardiac surgery. Further research is required to investigate the roles of these indices in the risk stratification of POAF in patients undergoing cardiac surgery.
- 1 January 2026
- Published by Wiley in Journal of Cardiac Surgery
- Vol. 2026 (1)
Open AccessAssociation of Platelet Count, Mean Platelet Volume, Platelet Distribution Width, Plateletcrit, and Platelet–Lymphocyte Ratio With Postoperative Cardiac Surgery–Associated Atrial Fibrillation: A Systematic Review and Meta‐Analysis
Background: The predictive value of platelet indices, including the platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), plateletcrit (PCT), and platelet–lymphocyte ratio (PLR) for postoperative atrial fibrillation (POAF) following cardiac surgery remains undetermined. Methods: MEDLINE, Embase, and the Cochrane Library were searched from inception to October 2024. For each included study, median differences (MDs) and odds ratios (ORs) were tabulated with 95% confidence intervals (CIs). Pooled estimates were generated using random‐effects inverse‐variance modeling. Statistical analysis focused on cases of POAF. Results: Six thousand five hundred and seventeen unique studies were screened and included 23 studies involving 12,375 patients in the subsequent analysis. Compared with patients who did not develop POAF, patients with POAF had higher preoperative MPV (MD: 0.30 fL, 95% CI: 0.07–0.53, and p = 0.0112) and PLR (MD: 40.42, 95% CI: 7.49–73.33, and p = 0.0161). Preoperative PLT (MD: 3.32, 95% CI: −5.87–12.51, and p = 0.4785) was not significantly different between groups. Study numbers were insufficient to assess the association between PCT with POAF. Conclusion: Elevated preoperative MPV and PLR were associated with POAF after cardiac surgery. Further research is required to investigate the roles of these indices in the risk stratification of POAF in patients undergoing cardiac surgery.
- 29 December 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 589-598
Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss
- 29 December 2025
- Published by Elsevier in Ophthalmology
- Vol. 133 (5) , 589-598
Rate and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy with Semaglutide Use for Diabetes and Weight Loss
- Open Access
- 20 November 2025
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 17
Nutraceuticals and neuroprotection for glaucoma—introducing the NP-10 System
Glaucoma, a leading global cause of irreversible blindness, often progresses despite adequate intraocular pressure (IOP) control, highlighting a crucial unmet need for neuroprotective strategies that directly promote retinal ganglion cell survival. In addition, the glaucoma standard of care is often reactive, initiating only on measurable structural or functional loss and lacking in structured, proactive approach to neuroprotection. This review introduces the NP-10 System, a novel conceptual framework designed to systematically address 10 diverse and interrelated neuroprotective mechanisms implicated in glaucomatous neurodegeneration. Broadly, these can be categorized as pressure-related factors (direct IOP and psychological stress), vascular factors (encompassing vascular dysregulation and homocysteine-related endothelial dysfunction), cellular dysfunctions (mitochondrial dysfunction, glycolysis impairment, oxidative stress, and chronic inflammation), and functional deficits (macular pigment deficiency and impaired axonal function). Specific nutraceutical interventions, including saffron, French maritime pine, bilberry, palmitoylethanolamide, nicotinamide, methylfolate, methylcobalamin, macular carotenoids, Ginkgo biloba, pyruvate, and citicoline, may target multiple mechanisms to reduce IOP, modulate stress, improve ocular perfusion, enhance cellular bioenergetics, provide antioxidant and anti-inflammatory benefits, augment macular pigment, and improve visual function in glaucoma. With promising emerging evidence for neuroprotection, the NP-10 System provides a scaffold for future large, randomized trials to establish clinical efficacy, optimize formulations, and clarify safety profiles of these nutraceuticals, paving the way for integrating targeted nutritional support into proactive glaucoma care.
- 20 November 2025
- Published by SAGE Publications in Therapeutic Advances in Ophthalmology
- Vol. 17
Open AccessNutraceuticals and neuroprotection for glaucoma—introducing the NP-10 System
Glaucoma, a leading global cause of irreversible blindness, often progresses despite adequate intraocular pressure (IOP) control, highlighting a crucial unmet need for neuroprotective strategies that directly promote retinal ganglion cell survival. In addition, the glaucoma standard of care is often reactive, initiating only on measurable structural or functional loss and lacking in structured, proactive approach to neuroprotection. This review introduces the NP-10 System, a novel conceptual framework designed to systematically address 10 diverse and interrelated neuroprotective mechanisms implicated in glaucomatous neurodegeneration. Broadly, these can be categorized as pressure-related factors (direct IOP and psychological stress), vascular factors (encompassing vascular dysregulation and homocysteine-related endothelial dysfunction), cellular dysfunctions (mitochondrial dysfunction, glycolysis impairment, oxidative stress, and chronic inflammation), and functional deficits (macular pigment deficiency and impaired axonal function). Specific nutraceutical interventions, including saffron, French maritime pine, bilberry, palmitoylethanolamide, nicotinamide, methylfolate, methylcobalamin, macular carotenoids, Ginkgo biloba, pyruvate, and citicoline, may target multiple mechanisms to reduce IOP, modulate stress, improve ocular perfusion, enhance cellular bioenergetics, provide antioxidant and anti-inflammatory benefits, augment macular pigment, and improve visual function in glaucoma. With promising emerging evidence for neuroprotection, the NP-10 System provides a scaffold for future large, randomized trials to establish clinical efficacy, optimize formulations, and clarify safety profiles of these nutraceuticals, paving the way for integrating targeted nutritional support into proactive glaucoma care.